Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.31 USD | +0.57% | -5.38% | -36.61% |
18/03 | Nu Skin Enterprises, Inc. Announces Retirement of Andrew Lipman as Board of Directors | CI |
15/02 | Sector Update: Consumer Stocks Advance Premarket Thursday | MT |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- With a P/E ratio at 12.37 for the current year and 8.29 for next year, earnings multiples are highly attractive compared with competitors.
- The stock, which is currently worth 2024 to 0.45 times its sales, is clearly overvalued in comparison with peers.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company does not generate enough profits, which is an alarming weak point.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Personal Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-36.61% | 611M | C+ | ||
+8.76% | 129B | B- | ||
+14.18% | 74.67B | A+ | ||
-16.59% | 62.59B | A- | ||
+0.82% | 52.86B | B+ | ||
-12.40% | 36.11B | - | ||
+3.54% | 33.57B | B- | ||
+7.92% | 17.29B | A- | ||
+6.30% | 14.75B | B | ||
-8.65% | 10.82B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NUS Stock
- Ratings Nu Skin Enterprises, Inc.